XSpray Pharma Financials
| XSPRAY Stock | SEK 42.10 0.10 0.24% |
XSpray |
Understanding current and past XSpray Pharma Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of XSpray Pharma's financial statements are interrelated, with each one affecting the others. For example, an increase in XSpray Pharma's assets may result in an increase in income on the income statement.
Please note, the presentation of XSpray Pharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, XSpray Pharma's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of XSpray Pharma's management manipulating its earnings.
XSpray Pharma Stock Summary
XSpray Pharma competes with Xbrane Biopharma, Hansa Biopharma, Cantargia, Vicore Pharma, and BioArctic. Xspray Pharma AB engages in developing protein kinase inhibitors for targeted cancer treatments in Sweden. Xspray Pharma AB was founded in 2003 and is based in Solna, Sweden. Xspray Pharma is traded on Stockholm Stock Exchange in Sweden.| Instrument | Sweden Stock View All |
| Exchange | Stockholm Exchange |
| ISIN | SE0009973563 |
| Business Address | Rsundavgen 12, Solna, |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.xspraypharma.com |
| Phone | 46 87 30 37 00 |
| Currency | SEK - Swedish Kronor |
You should never invest in XSpray Pharma without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of XSpray Stock, because this is throwing your money away. Analyzing the key information contained in XSpray Pharma's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
XSpray Pharma Key Financial Ratios
XSpray Pharma's financial ratios allow both analysts and investors to convert raw data from XSpray Pharma's financial statements into concise, actionable information that can be used to evaluate the performance of XSpray Pharma over time and compare it to other companies across industries.| Return On Equity | -0.24 | |||
| Return On Asset | -0.14 | |||
| Target Price | 135.0 | |||
| Number Of Employees | 26 | |||
| Beta | 0.97 |
XSpray Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining XSpray Pharma's current stock value. Our valuation model uses many indicators to compare XSpray Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across XSpray Pharma competition to find correlations between indicators driving XSpray Pharma's intrinsic value. More Info.XSpray Pharma AB is rated second in return on equity category among its peers. It is rated second in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value XSpray Pharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for XSpray Pharma's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.XSpray Pharma AB Systematic Risk
XSpray Pharma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. XSpray Pharma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was four with a total number of output elements of fifty-seven. The Beta measures systematic risk based on how returns on XSpray Pharma AB correlated with the market. If Beta is less than 0 XSpray Pharma generally moves in the opposite direction as compared to the market. If XSpray Pharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one XSpray Pharma AB is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of XSpray Pharma is generally in the same direction as the market. If Beta > 1 XSpray Pharma moves generally in the same direction as, but more than the movement of the benchmark.
XSpray Pharma November 27, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of XSpray Pharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of XSpray Pharma AB. We use our internally-developed statistical techniques to arrive at the intrinsic value of XSpray Pharma AB based on widely used predictive technical indicators. In general, we focus on analyzing XSpray Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build XSpray Pharma's daily price indicators and compare them against related drivers.
| Information Ratio | (0.12) | |||
| Maximum Drawdown | 25.5 | |||
| Value At Risk | (3.68) | |||
| Potential Upside | 5.26 |
Complementary Tools for XSpray Stock analysis
When running XSpray Pharma's price analysis, check to measure XSpray Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XSpray Pharma is operating at the current time. Most of XSpray Pharma's value examination focuses on studying past and present price action to predict the probability of XSpray Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XSpray Pharma's price. Additionally, you may evaluate how the addition of XSpray Pharma to your portfolios can decrease your overall portfolio volatility.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |